Probi to launch gut and immune health products in Taiwan with Alvogen

Probi has signed a distribution agreement with Alvogen IPCO S.Á.R.L, a multi
-national pharmaceutical company. Alvogen plans to launch Probi’s gut and immune
health products on the Taiwanese market in Q1 2013.
“Alvogen is a multi-national company with offices in over 20 countries with
ambitious plans for expansion in Asia. Taiwan is a very important market for
Alvogen and we are very pleased that they will launch both our consumer
healthcare products”, says Michael Oredsson, CEO of Probi.

Probi Digestis® is based on Lactobacillus plantarum 299v, which targets
bloating, gas formation and pain, common symptoms that are sometimes mild or
temporary but often more severe and diagnosed as IBS. Probi Defendum® is based
on the combination of two probiotic strains, Lactobacillus plantarum HEAL9 and
Lactobacillus paracasei 8700:2. This probiotic mix has been proven in large
clinical studies to prevent colds, significantly reduce cold symptoms and
shorten cold periods.

Probi Digestis®will be launched under the brand Alvogen IBS and Probi
Defendum®will be launched under Alvogen Contracold. Probi’s ingredient logotype
will be featured on pack to emphasise the high quality probiotic ingredients.
Both products will be sold via Alvogen’s field force targeting GPs and
Gastroenterologists (Probi Digestis®) and GPs and Pediatricians (Probi
Defendum®).

The information is such that Probi AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR FURTHER INFORMATION, CONTACT:

Michael Oredsson, CEO, Probi, phone +46 46 286 89 23 or mobile +46 707 18 89 30,
e-mail: michael.oredsson@probi.se
Niklas Bjärum, Vice President Marketing & Sales, Probi, phone +46 46 286 89 67
or mobile +46 705 38 88 64, e-mail: niklas.bjarum@probi.se

ABOUT PROBI

Probi is a leading player in the probiotic research and the development of
efficient and well-documented probiotics. The research areas include:
gastrointestinal tracts, immune system, metabolic syndrome and stress and
recovery. Probi’s customers are leading companies in the functional foods and
consumer healthcare business areas. Total income for 2011 was MSEK 95.0. Probi’s
share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has approximately
4,500 shareholders. For more information, please visit www.probi.com.

ABOUT ALVOGEN

Alvogen IPCO S.Á.R.L. is the next generation pharmaceuticals company. Our
business model ensures competitive advantage through focused in-house
capabilities and a network of partners for enhanced speed and flexibility. A
unique portfolio of high quality and difficult to make products fuels our
targeted growth strategy. Currently, Alvogen is in more than 20 countries around
the world with over 200 strategically selected pharmaceutical projects in
development and registration covering key therapeutic areas including
biosimilars. Robert Wessman is Alvogen‘s Chairman and CEO and leads a world
-class team with a proven industry track record aiming to build a top 10 global
generics player.